https://ir.opthea.com/static-files/bd59ddce-4c9c-46d1-82bf-790ed8b1f827
How did we miss this important and undoubtedly very positive update from last week’s JP Morgan San Francisco Healthcare Conference?!
From page 3 of the presentation:
„P3 clinical trials about 90% enrolled at the beginning of January 2024.
Anticipated patient enrollment: COAST 1Q2024, ShORe 2Q2024.
Topline data expected mid 2025.“
Given OPT‘s rather dire track record when it comes to meeting timelines, this is more than just a comforting bit of news.
The best possible scenario remains intact, that‘s reporting full enrollment BEFORE refinancing to get to top line read out.
Important milestone: 90% enrollment achieved, timeline confirmed!
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $321.4M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 49.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 7766 | 1 |
View Market Depth
| Last trade - 16.14pm 07/06/2024 (20 minute delay) ? |
| OPT (ASX) Chart |
Day chart unavailable